A European study says GlaxoSmithKline's Avandia reduced by 62% the number of people with high blood sugar who developed Type 2 diabetes. The study in the journal Lancet also said the drug had significant side effects, and some experts are calling attention to the increased risk for heart problems.
Serono has returned to GlaxoSmithKline for a deal after its effort to attract bids of at least $15 billion failed to generate any offers, according to people close to the situation, The Wall Street Journal reports.
An FDA advisory panel voted in favor of allowing GlaxoSmithKline to sell a low-dose version of its Xenical weight-loss drug over the counter as Alli. The panel's chairman said risks associated with the drug were low and it would be better for dieters than many of the unapproved dietary supplements currently offered.
Processing problems that created a logjam at a Puerto Rico plant led GlaxoSmithKline to advise U.S. doctors it will experience another shortage of Coreg for treating heart failure and high blood pressure and Avandamet for diabetes.
GlaxoSmithKline, seen as trailing rival Merck in getting a cervical cancer vaccine to market, said it still is in talks with the FDA about submitting its drug Cervarix for approval. GSK had been expected to announce a filing timetable before the end of 2005, while Merck's Gardasil already has been submitted to U.S. and European regulators.